首页|我国单倍体造血干细胞移植的现状和未来

我国单倍体造血干细胞移植的现状和未来

The present and future of haploidentical hematopoietic stem cell transplantation in China

扫码查看
供者缺乏是造血干细胞移植广泛使用的最大障碍.新型移植方案的建立、完善使得单倍体造血干细胞移植成为临床常规,大量血液病患者得以从中获益,单倍体供者已经成为中国异基因造血干细胞移植最重要的供者来源.本文聚焦单倍体造血干细胞移植在我国开展的现状及未来发展趋势,增加临床医师对单倍体造血干细胞移植的了解.
The lack of donors is the biggest obstacle to the widespread use of hematopoietic stem cell transplantation.The establishment and improvement of new transplantation schemes have made haploid hematopoietic stem cell transplantation a clinical routine,benefiting a large number of patients with hematological diseases.Haploid donors have become the most important source of donors for allogeneic hematopoietic stem cell transplantation in China.This article focuses on the current situation and future development trends of haploid hematopoietic stem cell transplantation in China,in order to increase the understanding of clinical doctors on haploid hematopoietic stem cell transplantation.

莫晓冬、黄晓军

展开 >

北京大学人民医院,北京大学血液病研究所,国家血液系统疾病临床医学研究中心,造血干细胞移植治疗血液病北京市重点实验室,北京 100044

国家重点研发计划国家重点研发计划国家自然科学基金面上项目

2022YFA11033002022YFC250260682170208

2024

中华血液学杂志
中华医学会

中华血液学杂志

CSTPCD北大核心
影响因子:1.17
ISSN:0253-2727
年,卷(期):2024.45(7)